{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:40:32Z","timestamp":1768869632425,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","award":["Sanofi Espa\u00f1a"],"award-info":[{"award-number":["Sanofi Espa\u00f1a"]}],"id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Its efficacy and safety have been widely demonstrated in clinical trials, but experience from real-world cohorts is also needed to support its clinical use. Quality of life (QoL) outcomes are an important complement to the clinical benefits of treatment, offering a patient-centered perspective on how the drug contributes to general well-being. In this line we aimed to evaluate the QoL of patients treated with alemtuzumab in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective 3-year multicenter study was carried out in adult patients diagnosed with RRMS who had started alemtuzumab according to clinical practice within 8 weeks before inclusion. The primary endpoint was the change in QoL over three years of treatment with alemtuzumab using the 29-item Multiple Sclerosis Impact Scale (MSIS-29). Secondary endpoints included changes from baseline in the 21-item Modified Fatigue Impact Scale (MFIS-21), Beck Depression Inventory (BDI-II), Symbol Digit Modalities Test (SDMT, oral version) and Work Productivity. Disability worsening was also assessed based on the Expanded Disability Status Scale (EDSS), along with the annualized relapse rate (ARR) and radiological activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A cohort of 165 patients was analyzed (mean age 38.6 years, mean disease duration 8.5 years, mean EDSS score 3.3). MSIS-29 physical domain scores decreased significantly from baseline by a mean of 7.2\u2009\u00b1\u20091.8 points at year 1, 6.4\u2009\u00b1\u20092.2 at year 2 and 5.6\u2009\u00b1\u20092.3 at year 3 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 in all cases). Similarly, MSIS-29 psychological domain scores decreased significantly by a mean of 7.9\u2009\u00b1\u20092.4 points at year 1, 12.8\u2009\u00b1\u20092.9 at year 2 and 13.2\u2009\u00b1\u20093.0 at year 3 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 in all cases). Significant reductions from baseline were also evidenced in MFIS-21 and BDI-II scores, while SDMT scores remained unchanged. During the 3 years on alemtuzumab, the ARR was 0.15, representing an 83% reduction from the 2 years before initiation. At 3 years, 81.5% of patients were free from radiological activity and 87% were free from disability worsening.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results indicate early and substantial improvements in patients\u2019 perception of their QoL and functioning with alemtuzumab that were sustained over three years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00822-9","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:18:41Z","timestamp":1734535121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-9890","authenticated-orcid":false,"given":"Jos\u00e9 Eustasio","family":"Meca-Lallana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena \u00c1lvarez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Forner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baldo","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.18502\/cjn.v21i3.11106","volume":"21","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh F, Balabandian M, Rostami MR, Owji M, Sahraian MA, Bidadian M et al (2022) Association of cognitive impairment and quality of life in patients with multiple sclerosis: a cross-sectional study. Curr J Neurol 21:144\u2013150. https:\/\/doi.org\/10.18502\/cjn.v21i3.11106","journal-title":"Curr J Neurol"},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.msard.2019.07.029","volume":"35","author":"S Schmidt","year":"2019","unstructured":"Schmidt S, Jostingmeyer P (2019) Depression, fatigue and disability are independently associated with quality of life in patients with multiple sclerosis: results of a cross-sectional study. Mult Scler Relat Disord 35:262\u2013269. https:\/\/doi.org\/10.1016\/j.msard.2019.07.029","journal-title":"Mult Scler Relat Disord"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5455\/medarh.2020.74.368-373","volume":"74","author":"A Sehanovic","year":"2020","unstructured":"Sehanovic A, Kunic S, Ibrahimagic OC, Smajlovic D, Tupkovic E, Mehicevic A et al (2020) Contributing factors to the quality of life in multiple sclerosis. Med Arch 74:368\u2013373. https:\/\/doi.org\/10.5455\/medarh.2020.74.368-373","journal-title":"Med Arch"},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"524894","DOI":"10.1155\/2013\/524894","volume":"2013","author":"K Baumstarck","year":"2013","unstructured":"Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P (2013) Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult Scler Int 2013:524894. https:\/\/doi.org\/10.1155\/2013\/524894","journal-title":"Mult Scler Int"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fneur.2017.00729","volume":"8","author":"MC Ysrraelit","year":"2017","unstructured":"Ysrraelit MC, Fiol MP, Gaitan MI, Correale J (2017) Quality of Life Assessment in multiple sclerosis: different perception between patients and neurologists. Front Neurol 8:729. https:\/\/doi.org\/10.3389\/fneur.2017.00729","journal-title":"Front Neurol"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"e09637","DOI":"10.1016\/j.heliyon.2022.e09637","volume":"8","author":"SB Reitzel","year":"2022","unstructured":"Reitzel SB, Lynning M, Skovgaard L (2022) Neurologists\u2019 views on patient reported outcomes in multiple sclerosis care. Heliyon 8:e09637. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09637","journal-title":"Heliyon"},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89:1117\u20131126. https:\/\/doi.org\/10.1212\/WNL.0000000000004354","journal-title":"Neurology"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","volume":"78","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW et al (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78:1069\u20131078. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8ee7","journal-title":"Neurology"},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89:1107\u20131116. https:\/\/doi.org\/10.1212\/WNL.0000000000004313","journal-title":"Neurology"},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"CT Investigators","year":"2008","unstructured":"Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa0802670","journal-title":"N Engl J Med"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"101504","DOI":"10.1016\/j.msard.2019.101504","volume":"38","author":"M di Ioia","year":"2020","unstructured":"di Ioia M, Di Stefano V, Farina D, Di Tommaso V, Travaglini D, Pietrolongo E et al (2020) Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord 38:101504. https:\/\/doi.org\/10.1016\/j.msard.2019.101504","journal-title":"Mult Scler Relat Disord"},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"1112193","DOI":"10.3389\/fneur.2023.1112193","volume":"14","author":"S Eichau","year":"2023","unstructured":"Eichau S, Lopez Ruiz R, Ruiz de Arcos M, Ruiz-Pena JL, Navarro G, Calleja MA et al (2023) Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: the RealMS study. Front Neurol 14:1112193. https:\/\/doi.org\/10.3389\/fneur.2023.1112193","journal-title":"Front Neurol"},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","volume":"266","author":"J Frau","year":"2019","unstructured":"Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E (2019) Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol 266:1405\u20131411. https:\/\/doi.org\/10.1007\/s00415-019-09272-6","journal-title":"J Neurol"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","volume":"265","author":"L Prosperini","year":"2018","unstructured":"Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M et al (2018) No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol 265:2851\u20132860. https:\/\/doi.org\/10.1007\/s00415-018-9070-x","journal-title":"J Neurol"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ene.15121","volume":"29","author":"CV Russo","year":"2022","unstructured":"Russo CV, Sacca F, Frau J, Annovazzi P, Signoriello E, Bonavita S et al (2022) A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol 29:257\u2013266. https:\/\/doi.org\/10.1111\/ene.15121","journal-title":"Eur J Neurol"},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"1265354","DOI":"10.3389\/fneur.2023.1265354","volume":"14","author":"S Sandgren","year":"2023","unstructured":"Sandgren S, Novakova L, Nordin A, Axelsson M, Malmestrom C, Zetterberg H et al (2023) A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis. Front Neurol 14:1265354. https:\/\/doi.org\/10.3389\/fneur.2023.1265354","journal-title":"Front Neurol"},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1177\/13524585211003291","volume":"27","author":"A Theodorsdottir","year":"2021","unstructured":"Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF et al (2021) Alemtuzumab treatment in Denmark: a national study based on the Danish multiple sclerosis Registry. Mult Scler 27:2254\u20132266. https:\/\/doi.org\/10.1177\/13524585211003291","journal-title":"Mult Scler"},{"key":"822_CR21","unstructured":"Ziemssen T, Hoffmann F, Richter S, Engelmann U, Quint L, Group T-MS (2021) Real-world effectiveness of alemtuzumab in RRMS patients in Germany: Interim results of the TREAT-MS study after completion of recruitment. In 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2021. October 13\u201315"},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1756285617722706","volume":"10","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Thomas K (2017) Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 10:343\u2013359. https:\/\/doi.org\/10.1177\/1756285617722706","journal-title":"Ther Adv Neurol Disord"},{"key":"822_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/1352458516677589","volume":"23","author":"R Arroyo Gonzalez","year":"2017","unstructured":"Arroyo Gonzalez R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL et al (2017) Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 23:1367\u20131376. https:\/\/doi.org\/10.1177\/1352458516677589","journal-title":"Mult Scler"},{"key":"822_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/1352458519849796","volume":"26","author":"R Arroyo","year":"2020","unstructured":"Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N et al (2020) Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. Mult Scler 26:955\u2013963. https:\/\/doi.org\/10.1177\/1352458519849796","journal-title":"Mult Scler"},{"key":"822_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40120-020-00191-7","volume":"9","author":"A Bertolotto","year":"2020","unstructured":"Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD et al (2020) Quality of Life improves with Alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients with or without autoimmune thyroid adverse events: Post Hoc Analysis of the CARE-MS studies. Neurol Ther 9:443\u2013457. https:\/\/doi.org\/10.1007\/s40120-020-00191-7","journal-title":"Neurol Ther"},{"key":"822_CR26","doi-asserted-by":"crossref","unstructured":"Bhupendra O, Khatri JM, Chung L, Poole E, Hashemi L (2019) Denise Bury: significant and clinically Meaningful Health-Related Quality of Life Improvements with Alemtuzumab in RRMS patients in clinical practice: interim results from a Prospective, non-interventional, real-world study (PROMiS) (P3.2-098). Neurology 92(15 Supplement)","DOI":"10.1212\/WNL.92.15_supplement.P3.2-098"},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"205521732211358","DOI":"10.1177\/20552173221135888","volume":"8","author":"S Wray","year":"2022","unstructured":"Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L et al (2022) Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: results from the real-world PRO-ACT study. Mult Scler J Exp Transl Clin 8:20552173221135888. https:\/\/doi.org\/10.1177\/20552173221135888","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"822_CR28","doi-asserted-by":"publisher","first-page":"103670","DOI":"10.1016\/j.msard.2022.103670","volume":"59","author":"S Rauber","year":"2022","unstructured":"Rauber S, Pawlitzki M, Korsen M, Kullmann JS, Thoene D, Pfeuffer S et al (2022) A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab. Mult Scler Relat Disord 59:103670. https:\/\/doi.org\/10.1016\/j.msard.2022.103670","journal-title":"Mult Scler Relat Disord"},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001) The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain 124:962\u2013973. https:\/\/doi.org\/10.1093\/brain\/124.5.962","journal-title":"Brain"},{"key":"822_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7224\/1537-2073.2012-019","volume":"15","author":"RD Larson","year":"2013","unstructured":"Larson RD (2013) Psychometric properties of the modified fatigue impact scale. Int J MS Care 15:15\u201320. https:\/\/doi.org\/10.7224\/1537-2073.2012-019","journal-title":"Int J MS Care"},{"key":"822_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561\u2013571. https:\/\/doi.org\/10.1001\/archpsyc.1961.01710120031004","journal-title":"Arch Gen Psychiatry"},{"key":"822_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12883-015-0296-2","volume":"15","author":"M Lopez-Gongora","year":"2015","unstructured":"Lopez-Gongora M, Querol L, Escartin A (2015) A one-year follow-up study of the Symbol Digit modalities Test (SDMT) and the Paced Auditory serial addition test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity. BMC Neurol 15:40. https:\/\/doi.org\/10.1186\/s12883-015-0296-2","journal-title":"BMC Neurol"},{"key":"822_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1191\/1352458505ms1117oa","volume":"11","author":"D Kos","year":"2005","unstructured":"Kos D, Kerckhofs E, Carrea I, Verza R, Ramos M, Jansa J (2005) Evaluation of the modified fatigue impact scale in four different European countries. Mult Scler 11:76\u201380. https:\/\/doi.org\/10.1191\/1352458505ms1117oa","journal-title":"Mult Scler"},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"102950","DOI":"10.1016\/j.msard.2021.102950","volume":"51","author":"J Sandry","year":"2021","unstructured":"Sandry J, Simonet DV, Brandstadter R, Krieger S, Katz Sand I, Graney RA et al (2021) The Symbol Digit modalities Test (SDMT) is sensitive but non-specific in MS: lexical access speed, memory, and information processing speed independently contribute to SDMT performance. Mult Scler Relat Disord 51:102950. https:\/\/doi.org\/10.1016\/j.msard.2021.102950","journal-title":"Mult Scler Relat Disord"},{"key":"822_CR35","doi-asserted-by":"publisher","unstructured":"Young CA, Rog DJ, Sharrack B, Tanasescu R, Kalra S, Chhetri SK et al (2024) Physical and psychological aspects of multiple sclerosis: revisiting the multiple sclerosis impact scale (MSIS-29). Mult Scler 13524585241288393. https:\/\/doi.org\/10.1177\/13524585241288393","DOI":"10.1177\/13524585241288393"},{"key":"822_CR36","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1352458514530489","volume":"20","author":"GA Phillips","year":"2014","unstructured":"Phillips GA, Wyrwich KW, Guo S, Medori R, Altincatal A, Wagner L et al (2014) Responder definition of the multiple sclerosis impact scale physical impact subscale for patients with physical worsening. Mult Scler 20:1753\u20131760. https:\/\/doi.org\/10.1177\/1352458514530489","journal-title":"Mult Scler"},{"key":"822_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jnnp.2006.105759","volume":"78","author":"L Costelloe","year":"2007","unstructured":"Costelloe L, O\u2019Rourke K, Kearney H, McGuigan C, Gribbin L, Duggan M et al (2007) The patient knows best: significant change in the physical component of the multiple sclerosis impact scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 78:841\u2013844. https:\/\/doi.org\/10.1136\/jnnp.2006.105759","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"822_CR38","doi-asserted-by":"publisher","first-page":"205521732312014","DOI":"10.1177\/20552173231201422","volume":"9","author":"A Regnault","year":"2023","unstructured":"Regnault A, Loubert A, Brennan R, Meunier J, Naujoks C, Cano S et al (2023) Does the multiple sclerosis impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies. Mult Scler J Exp Transl Clin 9:20552173231201422. https:\/\/doi.org\/10.1177\/20552173231201422","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"822_CR39","doi-asserted-by":"publisher","first-page":"104677","DOI":"10.1016\/j.msard.2023.104677","volume":"73","author":"J Wilken","year":"2023","unstructured":"Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T et al (2023) Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Mult Scler Relat Disord 73:104677. https:\/\/doi.org\/10.1016\/j.msard.2023.104677","journal-title":"Mult Scler Relat Disord"},{"key":"822_CR40","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1007\/s00415-022-11134-7","volume":"269","author":"LG Hvid","year":"2022","unstructured":"Hvid LG, Stenager E, Dalgas U (2022) Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study. J Neurol 269:4895\u20134908. https:\/\/doi.org\/10.1007\/s00415-022-11134-7","journal-title":"J Neurol"},{"key":"822_CR41","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fneur.2017.00730","volume":"8","author":"E Riepl","year":"2017","unstructured":"Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG et al (2017) Alemtuzumab improves cognitive Processing speed in active multiple Sclerosis-A longitudinal observational study. Front Neurol 8:730. https:\/\/doi.org\/10.3389\/fneur.2017.00730","journal-title":"Front Neurol"},{"key":"822_CR42","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s10072-019-03999-w","volume":"40","author":"DAM van Gorp","year":"2019","unstructured":"van Gorp DAM, van der Hiele K, Heerings MAP, Jongen PJ, van der Klink JJL, Reneman MF et al (2019) Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. Neurol Sci 40:2555\u20132564. https:\/\/doi.org\/10.1007\/s10072-019-03999-w","journal-title":"Neurol Sci"},{"key":"822_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","volume":"34","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J et al (2020) Efficacy and safety of Alemtuzumab through 9 years of follow-up in patients with highly active disease: Post Hoc Analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs 34:973\u2013988. https:\/\/doi.org\/10.1007\/s40263-020-00749-x","journal-title":"CNS Drugs"},{"key":"822_CR44","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1212\/WNL.0000000000002105","volume":"85","author":"N De Stefano","year":"2015","unstructured":"De Stefano N, Stromillo ML, Giorgio A, Battaglini M, Bartolozzi ML, Amato MP et al (2015) Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology 85:1722\u20131723. https:\/\/doi.org\/10.1212\/WNL.0000000000002105","journal-title":"Neurology"},{"key":"822_CR45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152\u2013158. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537","journal-title":"JAMA Neurol"},{"key":"822_CR46","unstructured":"European Medicines Agency Lemtrada 12\u00a0mg concentrate for solution for infusion: EU summary of product charateristics"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00822-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:17:56Z","timestamp":1734538676000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00822-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00822-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Hospital Cl\u00ednico San Carlos (Madrid, Spain). All patients were informed and gave written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JEML declares grants and consulting or speaking fees from Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Roche and Teva; SE declares speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva; BC declares grants from Sanofi Genzyme, Novartis, Merck, Roche, Biogen-Idec and Bristol-Myers-Squib; EAR declares consulting fees (Almirall, Bayer, Biogen, Novartis, Sanofi, Merck, Teva and Roche); AP declares personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Sanofi, Almirall, Bayer, Roche, Merck; MF and BT are Sanofi employees with ownership interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}